Immunotherapy safe within 90 days of radiation therapy for patients with cancer

Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.
“When new cancer drugs come on the market, they have usually been studied in patients with advanced cancers who have failed prior therapies. Drug study designs generally include a provision that prohibits giving other anticancer therapies within a prescribed time interval before the study drug is to be given, which is often between 2 and 4 weeks,”

Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.
“When new cancer drugs come on the market, they have usually been studied in patients with advanced cancers who have failed prior therapies. Drug study designs generally include a provision that prohibits giving other anticancer therapies within a prescribed time interval before the study drug is to be given, which is often between 2 and 4 weeks,”